Evidence map›Paper›PMID 28469517›Full record

ReviewClinical medicine insights. Pathology2017

A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.

Ebony N Gary, Michele A Kutzler

Abstract readReview
In one paragraph

Review in Clinical medicine insights. Pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ebony N GaryDepartment of Microbiology and Immunology, College of Medicine, Drexel University, Philadelphia, PA, USA.
Michele A KutzlerDepartment of Microbiology and Immunology, College of Medicine, Drexel University, Philadelphia, PA, USA.

Funding

T Cell Functionality After DNA and Adjuvant VaccinationP01AI071739 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WEINER, DAVID B. · 2007 to 2013
$10.1M
Interdisciplinary And Translational Research Training In NeurohivT32MH079785 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI Kamel Khalili · 2008 to 2026
$5.4M
TNT: Targeting and Triggering Adjuvancy of DNA VaccinesF32AI054152 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI KUTZLER, MICHELE AILEEN · 2003 to 2005
$139k
NIAID NIH HHS F32 AI054152NIAID NIH HHS P01 AI071739NIMH NIH HHS T32 MH079785
6 · The paper itself

Abstract

Human immunodeficiency virus 1 (HIV-1) is the causative agent of AIDS. There are currently more than 35 million people living with HIV infection worldwide, and more than 2 million new infections occur each year. The global pandemic caused by HIV-1 is the subject of numerous research projects, with the development of a prophylactic vaccine and a therapeutic cure being the ultimate goals. The classic paradigms of vaccinology have proven incapable of producing a viable vaccine due to the complexity of the virus' replication cycle, its genetic diversity, and a lack of understanding of the immune correlates of protection. Here, we briefly discuss recent vaccine approaches and the immune correlates of protection from HIV-1 infection with a focus on the role of the germinal center as a reservoir of replication-competent virus and its role in the development of broadly neutralizing antibodies in response to vaccination.

Indexed as

broadly neutralizing antibodyGerminal centerHIV-1TFHvaccines

Identifiers

PMID28469517
PMCPMC5398647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.